Takeda Pharmaceutical and the Indonesian government announced Sunday a partnership to establish a national plasma donation network [1].
This initiative aims to increase healthcare resilience by creating a sustainable local ecosystem for plasma-derived medicinal products. By reducing reliance on imports, the project seeks to ensure that lifesaving therapies are more equitably available to patients across the archipelago.
Takeda will invest up to $30 million [2] to develop the network. The collaboration involves several government entities, including the Ministry of Health, the Coordinating Ministry for Economic Affairs, and the Ministry of Investment and Downstream Industry, also known as BKPM [1].
The partnership focuses on the creation of an infrastructure capable of supporting the collection and processing of plasma. This system is designed to facilitate the production of plasma-derived medicinal products, which are essential for treating various rare and acute conditions [1].
According to the announcement made on July 12 [1], the project is a strategic move to strengthen the domestic health sector. The investment targets the development of a comprehensive ecosystem that integrates donation centers with the necessary medical oversight, and distribution channels.
By establishing this network, the Indonesian government and Takeda intend to bridge the gap in access to critical therapies. The project represents a shift toward downstream industrialization in the healthcare sector, a priority for the Ministry of Investment and Downstream Industry [1].
“Takeda will invest up to $30 million to develop the network.”
This investment signals a strategic shift for Indonesia toward pharmaceutical self-sufficiency. By building a domestic plasma donation network, the country reduces its vulnerability to global supply chain disruptions and lowers the cost of specialized medicines by eliminating a portion of the import dependency.
